Posterior cortical atrophy is a clinico-radiological syndrome characterized by progressive decline in visual processing and atrophy of posterior brain regions. With the majority of cases attributable to Alzheimer’s disease and recent evidence for genetic risk factors specifically related to posterior cortical atrophy, the syndrome can provide important insights into selective vulnerability and phenotypic diversity. The present study describes the first major longitudinal investigation of posterior cortical atrophy disease progression. Three hundred and sixty-one individuals (117 posterior cortical atrophy, 106 typical Alzheimer’s disease, 138 controls) fulfilling consensus criteria for posterior cortical atrophy-pure and typical Alzheim...
Introduction A classification framework for posterior cortical atrophy (PCA) is proposed to improve ...
Posterior cortical atrophy is an atypical form of Alzheimer’s disease characterized by visuospatial ...
With the prospect of disease-modifying drugs that will target the physiopathological process of Alzh...
Posterior cortical atrophy is a clinico-radiological syndrome characterized by progressive decline i...
SummaryPosterior cortical atrophy (PCA) is a neurodegenerative syndrome that is characterised by pro...
Posterior cortical atrophy (PCA) is a group of neurodegenerative dementing disorders characterized b...
This paper presents the first systematic review and meta-analysis of neuropsychological and brain mo...
Posterior cortical atrophy (PCA) is a group of neurodegenerative dementing disorders characterized b...
AbstractAge at onset (AAO) has been shown to influence the phenotype of Alzheimer's disease (AD), bu...
Posterior cortical atrophy is a neurodegenerative syndrome characterised by progressive disruption o...
Posterior cortical atrophy (PCA) is a rare neurodegenerative syndrome characterized by initial predo...
Posterior cortical atrophy (PCA) is a neurodegenerative syndrome characterized by predominant visual...
Age at onset (AAO) has been shown to influence the phenotype of Alzheimer's disease (AD), but how it...
OBJECTIVE: To determine whether atrophy relates to phenotypical variants of posterior cortical atrop...
Posterior cortical atrophy (PCA) is the canonical “visual dementia,” with affected individuals exper...
Introduction A classification framework for posterior cortical atrophy (PCA) is proposed to improve ...
Posterior cortical atrophy is an atypical form of Alzheimer’s disease characterized by visuospatial ...
With the prospect of disease-modifying drugs that will target the physiopathological process of Alzh...
Posterior cortical atrophy is a clinico-radiological syndrome characterized by progressive decline i...
SummaryPosterior cortical atrophy (PCA) is a neurodegenerative syndrome that is characterised by pro...
Posterior cortical atrophy (PCA) is a group of neurodegenerative dementing disorders characterized b...
This paper presents the first systematic review and meta-analysis of neuropsychological and brain mo...
Posterior cortical atrophy (PCA) is a group of neurodegenerative dementing disorders characterized b...
AbstractAge at onset (AAO) has been shown to influence the phenotype of Alzheimer's disease (AD), bu...
Posterior cortical atrophy is a neurodegenerative syndrome characterised by progressive disruption o...
Posterior cortical atrophy (PCA) is a rare neurodegenerative syndrome characterized by initial predo...
Posterior cortical atrophy (PCA) is a neurodegenerative syndrome characterized by predominant visual...
Age at onset (AAO) has been shown to influence the phenotype of Alzheimer's disease (AD), but how it...
OBJECTIVE: To determine whether atrophy relates to phenotypical variants of posterior cortical atrop...
Posterior cortical atrophy (PCA) is the canonical “visual dementia,” with affected individuals exper...
Introduction A classification framework for posterior cortical atrophy (PCA) is proposed to improve ...
Posterior cortical atrophy is an atypical form of Alzheimer’s disease characterized by visuospatial ...
With the prospect of disease-modifying drugs that will target the physiopathological process of Alzh...